Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 41-50 of 86 for hematology

  • Results filtered:
  • Study status: Open/Status Unknown
Edit search filters
  1. A Study Evaluating the Safety and Effectiveness of JCAR017 to Treat Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

    Jacksonville, FL, Rochester, MN

  2. A Study to Evaluate VSV-hIFNbeta-NIS to Treat Patients with Relapsed/Refractory Multiple Myleoma, Acute Myeloid Leukemia, or T-cell Lymphoma

    Rochester, MN, Scottsdale/Phoenix, AZ

  3. A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma

    Rochester, MN

  4. Cellular Immunotherapy for Viral Induced Cancer - EBV Positive Lymphomas

    Rochester, MN

  5. Safety/Efficacy of MEDI-551 in Combination With Immunomodulating Therapies in Subjects With Aggressive B-cell Lymphomas

    Rochester, MN

  6. ALEX Study: A Randomized, Phase III Study Comparing Alectinib with Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) Patients

    Scottsdale/Phoenix, AZ

  7. A Study of the Safety, Tolerability, Drug/Body Interactions, Biological and Clinical Activity of MSB0011359C (M7824) in Metastatic or Locally Advanced Solid Tumors

    Scottsdale/Phoenix, AZ

  8. Axicabtagene Ciloleucel versus Standard of Care Therapy as First-Line Therapy in High-Risk Large B-Cell Lymphoma

    Scottsdale/Phoenix, AZ, Rochester, MN, Albert Lea, MN, Eau Claire, WI, La Crosse, WI, Mankato, MN

  9. A Study to Provide Access to CTL019 Out of Specification Managed Access Program (MAP) for ALL or DLBCL Patients

    Scottsdale/Phoenix, AZ, Jacksonville, FL

  10. Hematology Electronic Consultations (e-Consults) the Mayo Clinic Experience

    Jacksonville, FL

.

Mayo Clinic Footer